Page data last changed: . Registry refreshes and identity assessments are separate from scientific content review.
Spadin-derived heptapeptide studied as a TREK-1 channel blocker.
Also known as: Spadin analog
Part of the Neuropeptides & signaling cluster
Overview
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
Source & context
Biological / chemical source: Synthetic shortened analog of spadin
Primary research or clinical context: Preclinical research compound (not authorized by Health Canada)
From spadin to a shorter analog
Spadin is a natural peptide fragment from the propeptide of sortilin that blocks TREK-1 channels. PE-22-28 was engineered as a shortened, more stable analog, exemplifying how sequence trimming can change potency and in vivo half-life.
Research status
Reported effects come from preclinical rodent models involving TREK-1 pharmacology and hippocampal signaling. No completed human efficacy trials are published, and this page provides no dosing or medical guidance.
Structure & chemistry
Molecular identity & reference confidence
Reference mass unavailable
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- PE-22-28 (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
FAQ about PE-22-28
What is PE-22-28?+
PE-22-28 is a synthetic heptapeptide derived from spadin, developed as a shortened analog that inhibits the TREK-1 potassium channel. It has been examined in rodent neuroscience studies and is not authorized as a medicine by Health Canada.
What Canadian product status is recorded for PE-22-28?+
Canadian product status for PE-22-28 has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of PE-22-28?+
PE-22-28 is commonly described as approximately 7 amino acids (Research peptide).
Related peptides
References & further reading
- 1.Djillani et al. (2019). Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin. Pharmacol Ther
- 2.Bae et al. (2020). Spadin Modulates Astrocytic Passive Conductance via Inhibition of TWIK-1/TREK-1 Heterodimeric Channels. Int J Mol Sci
- 3.Vallée et al. (2016). Fluoxetine Protection in Decompression Sickness in Mice is Enhanced by Blocking TREK-1 Potassium Channel with the "spadin" Antidepressant. Front Physiol
- 4.Djillani et al. (2017). Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity. Front Pharmacol
- 5.Hivelin et al. (2016). Potentiation of Calcium Influx and Insulin Secretion in Pancreatic Beta Cell by the Specific TREK-1 Blocker Spadin. J Diabetes Res
- 6.Ma et al. (2020). Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels. Front Pharmacol
- 7.Veyssiere et al. (2015). Retroinverso analogs of spadin display increased antidepressant effects. Psychopharmacology (Berl)
- 8.PMC — Shortened spadin analogs display better TREK-1 inhibition and in vivo stability (PMC5601071)